Nalini Chandar

Dr. Nalini Chandar

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2012 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HCHankui Chen
Hankui Chen
GRGrant Reed
Grant Reed
JGJanete Guardia
Janete Guardia
SLSandeep Lakhan
Sandeep Lakhan
OCOliver Couture
Oliver Couture
NCNalini Chandar
Nalini Chandar

1 May 2012 in Experimental Cell Research
Verified
Journal Article
Closed access
HCHankui Chen
Hankui Chen
KKKevin Kolman
Kevin Kolman
NLNatalie Lanciloti
Natalie Lanciloti
MNMichael Nerney
Michael Nerney
EHEmily Hays
Emily Hays
NCNalini Chandar
Nalini Chandar

1 September 2003 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
SBS. Bovenkerk
S. Bovenkerk
NLN. Lanciloti
N. Lanciloti
NCNalini Chandar
Nalini Chandar

1 November 2005 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
PDF file
NCNalini Chandar
Nalini Chandar
JSJohn Swindle
John Swindle
ASAnn Szajkovics
Ann Szajkovics
KKKevin Kolman
Kevin Kolman

29 July 2005 in Cancer Cell International
Verified
Journal Article
Open access
NCNalini Chandar
Nalini Chandar
RSRasleen Saluja
Rasleen Saluja
PLPeter C Lamar
Peter C Lamar
KKKevin Kolman
Kevin Kolman
WPWalter Prozialeck
Walter Prozialeck
Background: This study was undertaken to examine the relationship between the tumor suppressor gene p53 and the nuclear signaling protein beta-catenin during bone differentiation. Cross talk between p53 and beta-catenin pathways has been demonstrated and is important during tumorigenesis and DNA damage, where deregulation of beta catenin activates p53. In this study, we used estrogen treatment of osteoblasts as a paradigm to study the relationship between the two proteins during osteoblast differentiation. Results: We exposed osteoblast-like ROS17/2.8 cells to 17-beta estradiol (E2), in a short term assay, and studied the cellular distribution and expression of beta-catenin. We found beta-catenin to be up regulated several fold following E2 treatment. Levels of p53 and its functional activity mirrored the quantitative changes seen in beta-catenin. Alkaline phosphatase, an early marker of osteoblast differentiation, was increased in a manner similar to beta-catenin and p53. In order to determine if there was a direct relationship between alkaline phosphatase expression and beta-catenin, we used two different approaches. In the first approach, treatment with LiCl, which is known to activate beta-catenin, caused a several fold increase in alkaline phosphatase activity. In the second approach, transient transfection of wild type beta-catenin into osteoblasts increased alkaline phosphatase activity two fold over basal levels, showing that beta catenin expression can directly affect alkaline phosphatase expression. However increase in beta catenin activity was not associated with an increase in its signaling activity through TCF/LEF mediated transcription. Immunofluorescence analyses of p53 and beta-catenin localization showed that E2 first caused an increase in cytosolic beta-catenin followed by the accumulation of beta-catenin in the nucleus. Nuclear p53 localization was detected in several cells. Expression of p53 was accompanied by distribution of beta-catenin to the cytoplasm and cell borders. A sub population of cells staining strongly for both proteins appeared to be apoptotic. Conclusion: These results suggest that interactions between p53 and beta-catenin signaling pathways may play a key role in osteoblast differentiation and maintenance of tissue homeostasis.

23 August 2000
Verified
Journal Article
Closed access
NCNalini Chandar
Nalini Chandar
LDL Donehower
L Donehower
NLN Lanciloti
N Lanciloti